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Abstract
Background: A delay is evident between the development of new policies on TB diagnostics and their implementation at
country level. The Stop TB Partnership would benefit from information from national TB program (NTP) managers on
progress towards implementation of new recommendations as well as the opportunities and challenges encountered in the
process.
Methods and Findings: To solicit information on the introduction of new TB diagnostics at country level, questionnaires
were sent out to NTP managers of high-burden TB countries and a subset of managers was interviewed. The results indicate
that about 50% of high-burden TB countries are using the TB diagnostic tools newly recommended by the World Health
Organization (WHO). Most NTP managers reported that new diagnostics would only be implemented when officially
endorsed by the WHO. All countries have plans to adopt newly endorsed diagnostics at reference laboratory level, while
approaches to optimize smear microscopy at lower levels of the health service are given less attention. NTP managers
reported diverse challenges to the implementation of new diagnostics.
Conclusions: More information on the obstacles and advantages of introducing new diagnostic tools should be provided to
NTP managers to ensure the rational adoption of new diagnostics. A single recommendation covering the introduction of a
package of diagnostic tools might be preferable to NTP managers and facilitate implementation in high-burden TB
countries.
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Introduction
Tuberculosis (TB) is a leading global cause of morbidity and
mortality and control efforts have so far failed to substantially
reduce the burden of disease. Early case detection is critical to TB
control but has been problematic, at least partly, because of
limitations associated with diagnostic tools. Inadequate diagnostic
tools have also contributed to poor detection and poor control of
multi-drug resistant TB (MDR-TB) [1]. New diagnostic tools,
including new technologies and approaches, are becoming
available and are being endorsed by the World Health
Organization (WHO). National TB control programmes (NTPs)
are beginning to introduce these new diagnostic tools in their
diagnostic services and integrate them in national control activities
- a process referred to as ‘‘retooling’’. Diagnostic retooling for
control of other infectious diseases has often been slow and
significant delays can occur between tools becoming available and
their application in control activities. In 2006, the Stop TB
Partnership created a Task Force on Retooling to produce a
roadmap and other information to facilitate the process and to
help reduce this delay [2]. However, anecdotal information
suggests that there is still a time gap between WHO-endorsement
of new TB diagnostics and their adoption by NTPs. Identifying
and understanding this time gap is essential for successful
diagnostic retooling.
An audit was conducted in mid-2009 to assess progress in the
first phase of retooling, namely adopting new diagnostics by NTPs
in countries with a high burden of TB (HBCs) and/or a high-
burden of MDR-TB (HBC-MDR) [3]. This aimed to determine
whether delays were occurring and if so, to identify barriers to
retooling diagnostic services.
At the time of the audit five tools or approaches had recently
been endorsed by WHO. For reference laboratory level, these
were liquid TB culture and drug-susceptibility testing, rapid
speciation of liquid cultures, and molecular line probe assays
(MLPA) for rapid detection of MDR-TB [4,5]. For peripheral
laboratory level, WHO had endorsed the new definition for a
smear positive case and the reduction in the number of sputum
smears for the diagnosis of smear-positive pulmonary TB [6–9].
Two tools were being considered for endorsement by WHO at
the time of the survey, namely Light-Emitting Diodes (LED)
fluorescence microscopy and the collection of two sputum
samples on the same day (called ‘frontloaded’ smear-microscopy)
[10–12].
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Specifically, the audit was designed to answer the following
questions:
1. Is information on new tools and the process of retooling getting
to NTPs and national reference laboratories (NRLs)?
2. What retooling has taken place recently?
3. What future retooling is planned?
4. What do NTPs consider as constraints of retooling?
5. What do NTPs consider as benefits of retooling?
6. What factors determine whether retooling will take place or
not?
The work of the Task Force on Retooling has been
mainstreamed and is now the responsibility of the ‘‘Introducing
New Approaches and Tools’’ (INAT) Group within the DOTS
Expansion Working Group of the Stop TB Partnership. This audit
may inform future work of the INAT Group.
Methods
We set out to conduct an audit of retooling activities in 34
HBCs and/or HBC-MDRs, comprising of nine HBCs, 12 HBC-
MDRs and 13 HB- and HBC-MDRs. Questionnaires were sent in
March 2009 to 34 NTP managers in all WHO regions (AFRO,
AMRO, EMRO, EURO, SEARO and WPRO) with a request to
forward the document to their NRL managers.
To address question 1, information on new diagnostics and
retooling processes was sent to NTP and NRL managers through
electronic files and website links. Their ability to receive and open
a large electronic document and publications listed in the ‘‘further
reading’’ sections, as well as their ability to access publications
through website-based links was assessed.
To address questions 2 and 3, NTP and NRL managers were
asked about the status of retooling their NTPs with the seven
new diagnostics listed. The results are analyzed distinctively for
HBCs and/or HBC-MDRs. To address questions 4, the
questionnaires enquired about constraints experienced during
introduction of liquid TB culture, rapid speciation tests and
MLPA. Since NTP and NRL managers experience the
introduction of new tools from different perspectives, their
answers are discussed separately.
In addition, all NTP managers who responded to the
questionnaire were invited for a telephone interview to collect
qualitative data on retooling experiences that were not captured
by the questionnaire. NTP managers who agreed to participate
were sent information on the pre-determined structure and
content of the interview beforehand and their approval was
required for the transcripts afterwards. The pre-set open interview
questions asked about experienced constraints when adopting the
new positive case definition and reducing the number of sputum
smears, as well as benefits experienced or anticipated for patients,
laboratory staff and the NTP when introducing the seven new
diagnostics independently (question 5). An across-case analysis of
the interviews was performed to arrive at common concepts.
Finally, a with-in case analysis of each individual interview was
done to determine possible new considerations for resolving
research questions 6.
Ethical approval was not considered necessary for this audit.
Results
Respondents
Sixteen out of 34 (47%) HBCs and/or HBC-MDRs responded
to the questionnaire, of which four were HBCs, five were HBC-
MDRs, and seven were both HB- and HBC-MDRs. Only one
country returned two questionnaires filled out by the NTP and
NRL manager separately, thus in total 17 questionnaires were
collected. The other documents were completed by the NTP
manager only (11 countries) or the NRL managers only (four
countries). The responding countries represented a wide geo-
graphical distribution. Four interviews were conducted through
telephone calls with NTP managers from two HBCs in AFRO,
one HBC-MDR in EURO and one HB- and HBC-MDR in
WPRO.
Access to information on new tools and retooling
processes
Fourteen of the 17 respondents (all except three NTP managers)
received and were able to download an electronic document
describing the TB diagnostic pipeline. At the end of this document
16 publications for further reading were provided. The ability to
access them varied among the questionnaire respondents. Of those
that responded, the majority of NTP managers (5/9 or 56%) could
open eight documents or more, compared to a minority of NRL
managers (1/4 or 25%). These results indicate that NTP managers
had better access than NRL heads and could therefore be better
informed about new TB diagnostic tools.
Additionally, the respondents were provided with three direct
web-based links to WHO documents on TB diagnostic retooling.
Fourteen out of 16 respondents (94%, except one NRL heads and
one NTP manager) were able to access all three documents.
Apparently, it was more effective to provide information through
direct web-based linked documents than to have respondents
search further readings through a database themselves.
Retooling under way or completed
The current status of introducing the seven diagnostic tools in
NTPs is shown in Table 1. Out of the 16 countries that responded
to the questionnaire 10/16 (63%) had implemented liquid culture
in their laboratory networks and of those, 9/10 (90%) were using
rapid speciation tests. MLPA for drug resistance testing (DRT) had
been implemented in 7/16 (44%) HBCs and/or HBC-MDRs,
while 8/15 (53%) countries had adopted the new case definition.
The recommendation to reduce the number of sputum specimens
was implemented in 5/16 (31%) countries.
All respondents that had not implemented liquid culture (6/6)
planned to do so in the future. The same applied to countries not
using rapid methods for speciation (7/7) and MLPA (9/9). More
than half of HBCs and/or HBC-MDRs had plans to adopt
microscopy-optimizing tools (4/7 or 57% considered the new case
definition, 7/11 or 64% a reduction of the number of specimens
and 12/16 or 75% LED-fluorescence microscopy (FM)). Fron-
tloaded microscopy appeared a little less appealing; 7/16 (44%)
consider implementation. No apparent difference was seen
between HBCs and HBC-MDRs in wishing to adopt microsco-
py-improving diagnostics (data not shown). Most countries wishing
to adopt frontloaded and LED-FM would only do so with official
WHO endorsement (5/6 or 83% and 9/12 or 75% respectively,
data not shown).
Constraints experienced and anticipated
The questionnaires enquired about the constraints respondents
experienced during implementation of three tools, namely liquid
culture, rapid speciation tests, and MLPA for DRT. Table 1
shows all responses. The NTP managers that had introduced
liquid culture in their countries most often reported low staff
capacity and the supply of equipment and consumables into the
Retooling in TB Diagnostics
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country as obstacles for adopting the tool. The latter obstacle
was also reported most frequently by NRL managers. As
constraints of implementing rapid speciation tests, again low
personnel capacity and procurement of equipment are mostly
mentioned by NTP managers, while NRL managers note
supplies, maintenance of equipment and staff training. For
adoption of MLPA’s, NTP managers reported laboratory
infrastructure to be the most important obstacle, and supplies,
staff training and uninterrupted electrical power supply were
mentioned by NRL managers.
The interviews explored the experienced constraints four NTP
managers during the introduction of microscopy improving
tools. For the new case definition, respondents mostly mentioned
protocol changes and training laboratory staff as obstacles to
implementation. For the reduction of sputum samples, most of
them identified protocol changes and convincing laboratory staff
of the benefits as problems. Additionally, the interviews shed
light on the anticipated constraints faced by these NTP
managers during future implementation of LED-FM and
frontloaded microscopy. The overall costs of resources for
LED-FM and the training and convincing of laboratory
personnel required to adopt frontloaded microscopy were
considered major obstacles.
Benefits experienced and anticipated
From the interviews with four NTP managers it came forward
that the most important experienced benefit of adopting liquid
culture, rapid speciation and MLPA in NTPs was considered to be
more rapid identification of MDR-TB. All responses are shown in
Table 1. Furthermore, the majority of respondents believed that a
reduced time of diagnosis for the patient was a benefit of adopting
the new case definition and reducing the number of sputum
specimen. The advantages of LED-FM and front-loaded micros-
copy experienced by the respondents were also reduced time of
diagnosis for the patient, as well as reduced time of examination
for the technicians.
Table 1. Summary of survey results showing 16 high-burden TB (HBCs) and/or high-burden multi-drug resistant TB countries’
(HBC-MDRs) perspectives on retooling national TB programmes with seven new TB diagnostic tools.
Health Level New Tool/Approach
Tools introduced or under way
at country level
Constraints experienced/
anticipated by NTP and NRL
managers
Benefits experienced/
anticipated by NTP managers
Reference
laboratory
Liquid culture
(endorsed 2007) [4]
Introduced by 10 out of 16 countries:
2 HBCs, 5 HBC-MDRs, 3 HB- and
HBC-MDRs. 6 remaining countries
all consider adoption
7 NTP managers: low staff capacity,
procurement of equipment and
reagents, costs, QA system, lab
infrastructure, staff training. 3 NRL
managers: supply of equipment and
reagents, staff training, maintenance,
power supply, contamination
4 NTP managers: more rapid
detection of MDR-TB, reduced
time of diagnosis for
patient (Interviews)
Rapid speciation
(endorsed 2007) [4]
Introduced by 9 out of 16 countries:
2 HBCs, 5 HBC-MDRs, 2 HB- and
HBC-MDRs. 7 remaining countries
all consider adoption
7 NTP managers: low staff capacity,
procurement of equipment and
reagents, costs, QA system, lab
infrastructure. 2 NRL managers:
supply of equipment and reagents,
staff training, maintenance
4 NTP managers: rapid detection of
MDR-TB, reduced time of
diagnosis for patient (Interviews)
Molecular
line-probe assays
(endorsed 2008) [5]
Introduced by 7 out of 16 countries:
1 HBC, 3 HBC-MDRs, 3 HB- and
HBC-MDRs. 9 remaining countries
all consider adoption
5 NTP managers: lab infrastructure, staff
training and capacity, procurement
of equipment and reagents, sample
transportation. 2 NRL managers: staff
training, supply of consumables,
power supply
4 NTP managers: more rapid
detection of MDR-TB, simultaneous
genotyping, separating resistant
and sensitive patients (Interviews)
Peripheral
laboratory
New smear positive
case definition
(endorsed 2007) [6,7]
Introduced by 8 out of 15 countries:
3 HBCs, 4 HBC-MDRs, 1 HB- and
HBC-MDR. Of 7 remaining
countries 4 consider adoption
4 NTP managers: protocol changes,
training lab staff, QA system, staff
turnover, lack of evidence, overload
of recommendations (Interviews)
4 NTP managers: reduced time of
diagnosis for patient, reduced
workload, cost-savings, improved
case detection (Interviews)
Reduction in number of
specimens examined
(endorsed 2007) [8,9]
Introduced by 5 out of 16 countries:
3 HBCs, no HBC-MDRs, 2 HB- and
HBC-MDRs. Of 10 remaining
countries 7 consider adoption
4 NTP managers: protocol changes,
sensitizing lab staff, QA system, staff
training, lack of evidence, overload
of recommendations (Interviews)
4 NTP managers: reduced time of
diagnosis for patient, reduced
workload, cost-savings, improved
case detection (Interviews)
Light-emitting diode-
based fluorescence
microscopy [10,11]
12 out of 16 countries
consider retooling
4 NTP managers: costs of resources,
procurement of reagents, convincing
staff of benefits, staff training,
unsafe reagents, overload of
recommendations, lack of
expert advise (Interviews)
4 NTP managers: reduced
examination time, improved
case detection, high acceptance
among staff, ease of use,
cost-savings (Interviews)
Frontloaded
microscopy [12]
7 out of 16 countries
consider retooling
3 NTP managers: training lab staff
convincing lab staff of benefits,
logistic issues, lack of evidence,
increased workload, protocol
changes (Interviews)
4 NTP managers: reduced time of
diagnosis for patient, reduced
workload, cost-savings, improved
case detection (Interviews)
Legend. TB: tuberculosis. NTP: national TB programme. NRL: national TB reference laboratory. QA: quality assurance. Results were obtained through questionnaires
(and interviews where indicated).
doi:10.1371/journal.pone.0011649.t001
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Additional experiences/opinions gathered through
interviews
The with-in case analysis highlighted an interesting concept
repeated by one respondent and illustrated by the following quote:
‘‘For me as the manager who initiates these WHO recommended strategies there
should be very serious advantages for changing something. (…) It should be one
package of recommendations, not just recommend today one thing and tomorrow
another thing. This is the reason why I don’t initiate this change.’’
This respondent highlighted the difficulty for NTPs of
repeatedly dealing with a large number of new retooling
recommendations from WHO.
Additionally, respondents believed that other general challenges
had to be overcome before successful retooling could take place,
especially the establishment of a functional external quality
assessment system for microscopy and the enhancement of public
access to diagnostic services.
Discussion
This survey has shed light on NTP managers’ access to
information on new diagnostic tools and retooling. It appears that
information is accessible when provided through a direct web-
based link. Documents referenced or recommended for further
reading should be open-access or otherwise available through a
website. The New Diagnostics Working Group has recently
developed a site (www.tbevidence.org) that may serve this purpose
[13]. Secondly, the audit has mapped the progress of uptake of
new TB diagnostic policies in HBCs and/or HBC-MDRs. About
half of these countries have adopted the diagnostic tools newly
recommended by the WHO, except the reduction of the number
of patient sputum specimens to be examined by microscopy. More
advocacy may be needed if this last approach is to be adopted by
countries. The survey also demonstrated that implementers are
more disposed to adopting modern, technically demanding
diagnostic techniques than approaches to optimize smear
microscopy, though the latter is likely to remain the cornerstone
of TB diagnosis in HBCs for some considerable time. The results
suggest NTP staff feel that the introduction of frontloaded
microscopy in particular requires the provision of more field
evidence and information on specific advantages to NTPs. WHO
endorsement of any diagnostic tool was reported as critical in the
decision to introduce it to NTP activities. Since the audit was
conducted the evidence for LED-based fluorescence microscopy
and frontloaded microscopy has been systematically reviewed and
evaluated by a WHO-convened Expert Group Meeting. Both of
these diagnostic tools have now been endorsed by WHO [14,15].
The results ultimately illustrated that there is uncertainty among
some NTP staff on how to implement multiple recommendations
on new diagnostics from WHO. NTPs are required to introduce
new tools in a structured manner, often through a multi-year plan.
It may be helpful to offer a single recommendation covering the
introduction of a package of new diagnostic techniques and
approaches appropriate for particular settings. Donors, policy-
makers and technical agencies may find aspects of the NTP
perspective useful in supporting retooling activities at country
level.
This audit has addressed the opportunities and challenges
encountered in the process of implementing new diagnostics in
NTPs in a subjective manner. The sample size was small with 16
out of 34 HBCs and/or HBC-MDRs responding to the
questionnaire and four NTP managers were interviewed. The
non-responsive countries could have had different opinions about
the benefits and obstacles related to introducing new tools.
Therefore, surveys with a broader scope and more objective
indicators are required to prioritize these opinions and make
sound assumptions about (cost-effective) benefits of introducing
new tools. Finally, future studies assessing the success of diagnostic
retooling should not only explore the adoption of new tools by
NTPs, but also their integration into national TB control activities.
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